Remission of myasthenia gravis with MuSK antibodies during ruxolitinib treatment.
Institute of Neurology, Largo F. Vito, 1 - 00168, Catholic University, Rome, Italy.
Paolo E
PE
Alboini
Institute of Neurology, Largo F. Vito, 1 - 00168, Catholic University, Rome, Italy.
Amelia
A
Evoli
Institute of Neurology, Largo F. Vito, 1 - 00168, Catholic University, Rome, Italy.
Valentina
V
Damato
Institute of Neurology, Largo F. Vito, 1 - 00168, Catholic University, Rome, Italy.
Raffaele
R
Iorio
General Pathology, Catholic University, Rome, Italy.
Emanuela
E
Bartoccioni
D000368:Aged; D001323:Autoantibodies / Q000276:immunology; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications / Q000276:immunology / Q000503:physiopathology*; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D020794:Receptor Protein-Tyrosine Kinases / Q000276:immunology; D011950:Receptors, Cholinergic / Q000276:immunology; D012074:Remission Induction
D001323:Autoantibodies; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; D011950:Receptors, Cholinergic; C540383:ruxolitinib; C095714:MUSK protein, human; D020794:Receptor Protein-Tyrosine Kinases
JAK/STAT; JAK/STAT inhibitors; MuSK; myasthenia gravis; myelofibrosis; ruxolitinib